Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK6 | Q13882 | 10/20 | 0.40 |
| ▸ | JAK2 | O60674 | 5/20 | 0.37 |
| ▸ | JAK1 | P23458 | 5/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.34 |
| ▸ | LCK | P06239 | 4/20 | 0.34 |
| ▸ | MAPKAPK5 | Q8IW41 | 2/20 | 0.33 |
| ▸ | TTK | P33981 | 2/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25167695 | 0.94 | PTK6 (0.40) | PTK6JAK2JAK1AURKBLCK | |
| SCHEMBL25173549 | 0.94 | PTK6 (0.40) | PTK6JAK2JAK1AURKBLCK | |
| SCHEMBL30385736 | 0.94 | PTK6 (0.37) | PTK6JAK2JAK1 | |
| SCHEMBL22153365 | 0.92 | PTK6 (0.48) | PTK6JAK2JAK1AURKBLCK | |
| SCHEMBL25176078 | 0.92 | PTK6 (0.42) | PTK6JAK2JAK1AURKBLCK | |
| SCHEMBL30386118 | 0.91 | PTK6 (0.38) | PTK6JAK2JAK1CDK2 | |
| SCHEMBL30386112 | 0.91 | PTK6 (0.38) | PTK6JAK2JAK1CDK2 | |
| SCHEMBL25170405 | 0.91 | PTK6 (0.38) | PTK6JAK2JAK1CDK2 | |
| SCHEMBL25170424 | 0.91 | PTK6 (0.41) | PTK6JAK2JAK1AURKBLCK | |
| SCHEMBL22124270 | 0.90 | PTK6 (0.40) | PTK6JAK2JAK1AURKBLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4161931-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2026-02-18 | — | — | EP | disclosed |
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4161931-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | IKZF3, RRP15, IK | PTK6 925/4885JAK2 57/4885JAK1 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.